Fatigue in patients with multiple sclerosis: Is it related to pro- and anti-inflammatory cytokines?

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Malekzadeh, Arjan ^a,b   Van De Geer Peeters, Wietske ^a   De Groot, Vincent ^a,b   Elisabeth Teunissen, Charlotte ^a,b   Beckerman, Heleen ^a,b   Study Group, Trefams Ace ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY CYTOKINE; CYTOKINE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; PROINFLAMMATORY CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; FATIGUE; FEMALE; HUMAN; MALE; MIDDLE AGED; MOTIVATION; MULTIPLE SCLEROSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; ADOLESCENT; AGED; BLOOD; COMPLICATION; CONTROLLED CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; FATIGUE; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922324550     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/758314     Document Type: Article

References (36)

1. A. Compston and A. Coles, Multiple sclerosis, The Lancet, vol. 372, no. 9648, pp. 1502-1517, 2008.
2. R. Milo and E. Kahana, Multiple sclerosis: geoepidemiology, genetics and the environment, Autoimmunity Reviews, vol. 9, no. 5, pp.A387-A394, 2010.
3. H. J. Crayton and H. S. Rossman, Managing the symptoms of multiple sclerosis: a multimodal approach, Clinical Therapeutics, vol. 28, no. 4, pp. 445-460, 2006.
4. K. van Kessel and R. Moss-Morris, Understanding multiple sclerosis fatigue: a synthesis of biological and psychological factors, Journal of Psychosomatic Research, vol. 61, no. 5, pp. 583-585, 2006.
5. D. Kos, E. Kerckhofs, G. Nagels, M. B. Dhooghe, and S. Ilsbroukx, Reviewarticle: origin of fatigue inmultiple sclerosis: review of the literature, Neurorehabilitation and Neural Repair, vol. 22, no. 1, pp. 91-100, 2008.
6. R. Bakshi, Fatigue associated withmultiple sclerosis: diagnosis, impact and management, Multiple Sclerosis, vol. 9, no. 3, pp. 219-227, 2003.
7. E. Pucci, P. Branãs, R. DAmico, G. Giuliani, A. Solari, and C. Taus, Amantadine for fatigue in multiple sclerosis, Cochrane Database of Systematic Reviews, no. 1, Article ID CD002818, 2007.
8. C. Heesen, L. Nawrath, C. Reich, N. Bauer, K.-H. Schulz, and S. M. Gold, Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 1, pp. 34-39, 2006.
9. I. L. Simone, A. Ceccarelli, C. Tortorella et al., Influence of Interferon beta treatment on quality of life in multiple sclerosis patients, Health and Quality of Life Outcomes, vol. 4, article 96, 2006.
10. K. A. Lee, C. L. Gay, A. Lerdal, C. R. Pullinger, and B. E. Aouizerat, Cytokine polymorphisms are associated with fatigue in adults living with HIV/AIDS, Brain, Behavior, and Immunity, vol. 40, pp. 95-103, 2014.
11. H. J. Cho, M. Kivimäki, J. E. Bower, and M. R. Irwin, Association of C-reactive protein and interleukin-6 with newonset fatigue in the Whitehall II Prospective Cohort Study, Psychological Medicine, vol. 43, no. 8, pp. 1773-1783, 2013.
12. F. Kapsimalis, M. Basta, G. Varouchakis, K. Gourgoulianis, A. Vgontzas, and M. Kryger, Cytokines and pathological sleep, Sleep Medicine, vol. 9, no. 6, pp. 603-614, 2008.
13. V. De Groot, H. Beckerman, G. J. Lankhorst, and L.M. Bouter, How to measure comorbidity: a critical review of available methods, Journal of Clinical Epidemiology, vol. 56, no. 3, pp. 221-229, 2003.
14. B. S. Linn, M.W. Linn, and L. Gurel, Cumulative illness rating scale, Journal of the American Geriatrics Society, vol. 16, no. 5, pp. 622-626, 1968.
15. A. J. H. M. Beurskens, U. Bültmann, I. Kant, J. H. M. M. Vercoulen, G. Bleijenberg, and G. M. H. Swaen, Fatigue among working people: validity of a questionnaire measure, Occupational and Environmental Medicine, vol. 57, no. 5, pp. 353-357, 2000.
16. J. H. M. M. Vercoulen, O. R. Hommes, C. M. A. Swanink et al., Themeasurement of fatigue in patients withmultiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects, Archives of Neurology, vol. 53, no. 7, pp. 642-649, 1996.
17. H. Beckerman, L. J. M. Blikman, M. Heine et al., The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme, Trials, vol. 14, no. 1, article 250, 2013.
18. J. F. Kurtzke, Rating neurologic impairment inmultiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol. 33, no. 11, pp. 1444-1452, 1983.
19. A. S. Rigby, Statistical methods in epidemiology. VI. Correlation and regression: the same or different? Disability and Rehabilitation, vol. 22, no. 18, pp. 813-819, 2000.
20. J. W. R. Twisk, Inleiding in de Toegepaste Biostatistiek, Elsevier, Gezondheidszorg, The Netherlands, 2nd edition, 2010.
21. F. Chowdhury, A. Williams, and P. Johnson, Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling, Journal of Immunological Methods, vol. 340, no. 1, pp. 55-64, 2009.
22. D.Dabitao, J.B.Margolick, J.Lopez, and J.H. Bream, Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array, Journal of Immunological Methods, vol. 372, no. 1-2, pp. 71-77, 2011.
23. A.Malekzadeh, V. De Groot, H. Beckerman, B. W. VanOosten, M. A. Blankenstein, andC.Teunissen, Challenges inmulti-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases, Methods, vol. 56, no. 4, pp. 508-513, 2012.
24. S. Greenland, Multiple comparisons and association selection in general epidemiology, International Journal of Epidemiology, vol. 37, no. 3, pp. 430-434, 2008.
25. G. Giovannoni, A. J. Thompson, D. H. Miller, and E. J. Thompson, Fatigue is not associated with raised inflammatory markers inmultiple sclerosis, Neurology, vol. 57, no. 4, pp. 676- 681, 2001.
26. P. Flachenecker, I. Bihler, F.Weber, M. Gottschalk, K. V. Toyka, and P. Rieckmann, Cytokine mRNA expression in patients with multiple sclerosis and fatigue, Multiple Sclerosis, vol. 10, no. 2, pp. 165-169, 2004.
27. A. Malekzadeh and C. Teunissen, Recent progress in omicsdriven analysis of MS to unravel pathological mechanisms, Expert Review of Neurotherapeutics, vol. 13, no. 9, pp. 1001-1016, 2013.
28. R. G. Elbers, M. B. Rietberg, E. E. H. van Wegen et al., Selfreport fatigue questionnaires in multiple sclerosis, Parkinsons disease and stroke: a systematic review of measurement properties, Quality of Life Research, vol. 21, no. 6, pp. 925-944, 2012.
29. M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci, Interleukin-6 in aging and chronic disease: a magnificent pathway, Journals of Gerontology-Series A Biological Sciences and Medical Sciences, vol. 61, no. 6, pp. 575-584, 2006.
30. R. P. Stowe, M. K. Peek, M. P. Cutchin, and J. S. Goodwin, Plasma cytokine levels in a population-based study: relation to age and ethnicity, Journals of Gerontology-Series A Biological Sciences and Medical Sciences, vol. 65, no. 4, pp. 429-433, 2010.
31. R. A. Gadient and U. H. Otten, Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials, Progress in Neurobiology, vol. 52, no. 5, pp. 379-390, 1997.
32. N. Rohleder,M. Aringer, and M. Boentert, Role of interleukin- 6 in stress, sleep, and fatigue, Annals of the New York Academy of Sciences, vol. 1261, no. 1, pp. 88-96, 2012.
33. M. Sorenson, L. Janusek, and H.Mathews, Psychological stress and cytokine production in multiple sclerosis: correlation with disease symptomatology, Biological Research for Nursing, vol. 15, no. 2, pp. 226-233, 2013.
34. C.Schubert, S.Hong,L.Natarajan,P. J.Mills, and J. E.Dimsdale, The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review, Brain, Behavior, and Immunity, vol. 21, no. 4, pp. 413-427, 2007.
35. D. Lindqvist, E. Kaufman, L. Brundin, S. Hall, Y. Surova, and O. Hansson, Non-motor symptoms in patients with Parkinsons disease-correlations with inflammatory cytokines in serum, PLoS ONE, vol. 7, no. 10, Article IDe47387, 2012.
36. P. K. Stys, G. W. Zamponi, J. van Minnen, and J. J. G. Geurts, Will the real multiple sclerosis please stand up? Nature Reviews Neuroscience, vol. 13, no. 7, pp. 507-514, 2012.